U.S. hospice agencies promise to be available around-the-clock to help patients dying in their homes. But a Kaiser Health News investigation shows that in an alarming number of cases, that promise is broken.
Overtreatment of breast cancer and other diseases is pervasive, burdening patients and the health care system with enormous costs and needless suffering.
Patients flocked to researcher who ignored usual patient protections, as university claimed ignorance.
Some teens and young adults are spending weeks or even months in retrofitted emergency rooms — even in mesh-covered tents — until specialized care can be found. ‘It’s a huge problem,’ one doctor says.
Despite a lack of medical training, relatives increasingly are assigned complex, risky medical tasks at home, such as maintaining catheters. If done incorrectly, blood clots, infections, even death can result.
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
The market for wound care products booms among a growing older and diabetic patient pool, but many treatments are untested and funding for research falls short.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Prosecutors say hedge-fund traders made millions trading on information leaked from Medicare.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
President-elect Donald Trump’s Cabinet pick Tom Price “assisted” a company and campaign donor who tapped executives with an urgent request to donate.
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”
Rep. Tom Price advocated on everything from a sperm test to a hot pepper ingredient on behalf of medical interests that included campaign donors.